Jivan Launches First Phosphodiesterase Splice Variant Array

Berkeley, CA (November 18, 2003) -- Jivan Biologics, Inc., a privately held company, today launched the first splice variant microarray for the phosphodiesterase (PDE) gene family.

"TransExpress™ Phosphodieserase provides the means to comprehensively investigate alternative splicing in this important gene family.," said Subha Srinivasan, Ph.D., Jivan's Chief Executive. "There has been increased attention devoted to phosphodiesterases after the approval of sildenafil and other PDE inhibitors. TransExpress™ Phosphodieserase will help researchers to understand the splicing patterns of phosphodiesterases and the effects of drug treatment."

The TransExpress™ Phosphodieserase splice variant array includes oligonucleotide probes for all exon-exon junctions of human PDE genes in RefSeq and in the public EST databases. TransExpress™ Phosphodiesterase microarrays can be used to profile the splicing of known splice isoforms, to discover novel splicing patterns, and to measure gene expression.

With TransExpress™ Phosphodiesterase, researches can identify molecular signatures for disease, monitor the effects of drug on PDE splicing, and find tissue- and patient-specific splicing patterns.

Jivan Biologics is a pioneer of high-throughput solutions to measure alternative splicing in vitro. Jivan Biologics' flagship TransExpress™ microarrays for alternative splicing provide pharmaceutical and biotechnology partners with greater precision and accuracy in disease profiling by comprehensively measuring the expression and changes in RNA splicing across entire protein families and pathways. For more information, please visit www.jivanbio.com.